37621 |
Medicine, General & Internal |
KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors |
NEW ENGL J MED 2020 10.1056/NEJMoa1917239 |
박근칠 |
2020 |
37620 |
Multidisciplinary Sciences |
Metabolic radiogenomics in lung cancer associations between FDG PET im... |
SCI REP-UK 2020 10.1038/s41598-020-70168-x |
박근칠 |
2020 |
37619 |
Immunology |
Immunological Characteristics of Hyperprogressive Disease in Patients ... |
IMMUNE NETW 2020 10.4110/in.2020.20.e48 |
박근칠 |
2020 |
37618 |
Oncology |
HLA-corrected tumor mutation burden and homologous recombination de fi... |
ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 |
박근칠 |
2020 |
37617 |
Oncology; Respiratory System |
Final overall survival and safety update for durvalumab in third- or l... |
LUNG CANCER 2020 10.1016/j.lungcan.2020.06.032 |
박근칠 |
2020 |
37616 |
Pharmacology & Pharmacy |
Evaluating entrectinib as a treatment option for non-small cell lung c... |
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 |
박근칠 |
2020 |
37615 |
Oncology |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell L... |
CANCER RES TREAT 2020 10.4143/crt.2020.278 |
박근칠 |
2020 |
37614 |
Medicine, General & Internal |
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung C... |
NEW ENGL J MED 2020 10.1056/NEJMoa2005653 |
박근칠 |
2020 |
37613 |
Oncology |
Clinical outcomes of immune checkpoint inhibitors for patients with re... |
BMC CANCER 2020 10.1186/s12885-020-07214-4 |
박근칠 |
2020 |
37612 |
Oncology; Immunology |
Clinical advantage of targeted sequencing for unbiased tumor mutationa... |
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 |
박근칠 |
2020 |